Danaher (NYSE:DHR)‘s stock had its “buy” rating reiterated by equities research analysts at Cowen in a research note issued on Tuesday, January 30th. They currently have a $110.00 price target on the conglomerate’s stock. Cowen’s price target would indicate a potential upside of 14.46% from the company’s current price.
Other equities research analysts have also issued reports about the stock. Robert W. Baird restated a “buy” rating and issued a $99.00 price objective on shares of Danaher in a report on Friday, December 15th. Citigroup raised their price objective on shares of Danaher to $107.00 and gave the company a “buy” rating in a report on Friday, December 15th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $110.00 target price on shares of Danaher in a research report on Friday, January 19th. Zacks Investment Research raised shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a research report on Thursday, October 5th. Finally, UBS Group initiated coverage on shares of Danaher in a research report on Monday, January 22nd. They issued a “buy” rating and a $99.97 target price on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $100.13.
Danaher (DHR) opened at $96.10 on Tuesday. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.39. Danaher has a fifty-two week low of $78.97 and a fifty-two week high of $104.82. The company has a market cap of $66,850.00, a P/E ratio of 27.46, a PEG ratio of 2.01 and a beta of 1.04.
Danaher (NYSE:DHR) last released its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The company had revenue of $5.09 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the business earned $1.05 EPS. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. research analysts anticipate that Danaher will post 4.37 earnings per share for the current year.
In other Danaher news, EVP William K. Daniel sold 131,066 shares of Danaher stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $102.05, for a total transaction of $13,375,285.30. Following the completion of the transaction, the executive vice president now owns 270,523 shares in the company, valued at $27,606,872.15. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Angela S. Lalor sold 42,988 shares of Danaher stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $102.29, for a total transaction of $4,397,242.52. Following the transaction, the senior vice president now owns 82,008 shares of the company’s stock, valued at approximately $8,388,598.32. The disclosure for this sale can be found here. Insiders sold 237,043 shares of company stock valued at $24,194,886 in the last quarter. Company insiders own 12.20% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. grew its holdings in shares of Danaher by 276.8% during the third quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock worth $225,332,000 after buying an additional 1,929,751 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Danaher by 4.6% during the fourth quarter. BlackRock Inc. now owns 40,984,366 shares of the conglomerate’s stock worth $3,804,169,000 after buying an additional 1,789,474 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Danaher by 16,410.0% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock worth $125,395,000 after buying an additional 1,476,901 shares in the last quarter. Findlay Park Partners LLP grew its holdings in shares of Danaher by 52.9% during the third quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock worth $353,186,000 after buying an additional 1,425,000 shares in the last quarter. Finally, Koch Industries Inc. grew its holdings in shares of Danaher by 29,127.3% during the second quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock worth $1,388,000 after buying an additional 1,399,859 shares in the last quarter. Institutional investors own 75.88% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/15/danahers-dhr-buy-rating-reaffirmed-at-cowen.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.